Seeking Alpha

ThinkEquity piles on to Navidea's (NAVB -27.4%) travails today, downgrading the shares to Hold...

ThinkEquity piles on to Navidea's (NAVB -27.4%) travails today, downgrading the shares to Hold on the back of the FDA's rejection of its Lymphoseek application and lack any of visibility on the FDA's review process going forward. The firm also slashes its price target to $2.50 from $7.
Comments (1)
  • New Low Observer
    , contributor
    Comments (2043) | Send Message
     
    Well then, that was a slam dunk ThinkEquity.

     

    Regards.
    11 Sep 2012, 02:08 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|